文献速递药物不良反应与药物警戒特殊人群用药

相同INN「伊米苷酶」用于不同药品对不良事件报告的影响:一项全球安全性数据库分析

Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
PubMed 文献 · Drug Saf · 2022-01-12

研究分析赛诺菲全球安全性数据库中,Abcertin与Asbroder采用相同INN「伊米苷酶」对不良事件报告的影响。第一项分析检索2012年1月至2018年3月提及Abcertin或Asbroder的病例;第二项分析比较墨西哥2015年Asbroder获批前后报告变化。结果显示相同INN使用可能混淆药物归因并影响药物警戒数据。

要点

  • 相同INN使Cerezyme安全性数据可能混入其他产品,导致药物警戒数据不准确。
  • 墨西哥Asbroder获批后伊米苷酶病例和不良事件数明显增加。
  • 部分病例显示患者联用Asbroder与Cerezyme,提示相同INN可能误导可互换性。

核心结论

  • 相同INN使用可能导致Cerezyme的汇总安全性特征包含其他采用相同INN的产品,造成药物警戒数据不准确。
  • 相同INN使用可能促使医疗保健提供者发生产品转换、替代或错误假设产品间可互换。
  • 不附加品牌名区分的相同INN使用可能掩盖产品间安全性特征的差异。

研究设计与样本

  • 研究分析赛诺菲全球安全性数据库中伊米苷酶个体病例安全性报告。
  • 第一项分析检索2012年1月至2018年3月叙述中提及Abcertin或Asbroder的病例。
  • 第二项分析检查墨西哥2013年5月至2018年3月报告的病例,评估2015年Asbroder在墨西哥获批后报告变化。

主要发现

  • 第二项分析中,Asbroder获批前为73例报告150例不良事件,获批后为132例报告333例不良事件。
  • 输注相关反应发生于25/132例,其中17例与Asbroder相关,6例与Cerezyme相关,2例不确定。

临床怎么用

  • 临床应意识到相同INN可能不代表产品可互换,尤其对于未按生物类似药路径批准的产品。
  • 药物警戒归因时应结合品牌名核实具体产品,避免将不良事件错误归因于原研产品。
  • 医疗保健提供者应避免仅基于相同INN假设产品间可互换或替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Approved in 1994 and assigned the International Nonproprietary Name (INN) imiglucerase by the World Health Organization, Cerezyme® (Sanofi Genzyme) is an enzyme replacement therapy used to treat Gaucher disease in > 90 countries. At least two therapies approved outside the USA and the European Union, Abcertin® and Asbroder®, have adopted the identical INN imiglucerase. Both drugs were approved via regulatory pathways not aligned with World Health Organization Similar Biotherapeutic Product guidelines. OBJECTIVE: We analyzed whether the use of the identical INN "imiglucerase" for these drugs impacts adverse event (AE) reporting in the Sanofi Global Safety Database. METHODS: First, we reviewed all imiglucerase individual case safety reports (referred to as cases) including AE data reported between January 2012 and March 2018 that contained Abcertin or Asbroder in the narrative. In a second analysis, we examined cases from Mexico reported between May 2013 and March 2018 to assess changes in imiglucerase reporting following the 2015 approval of Asbroder in Mexico. RESULTS: Fifty-six cases mentioning Asbroder and none mentioning Abcertin were retrieved in the first analysis. Upon close review, the AEs of 45 cases (80.4%) were attributed to Asbroder, one (1.8%) to Cerezyme; the specific drug attribution for the AEs of ten cases (17.9%) could not be determined. In the second analysis, a substantial increase in cases and AEs was observed in the period after Asbroder approval (73 cases with 150 AEs pre-approval vs 132 cases with 333 AEs post-approval). Twenty-three of 132 (17.4%) post-approval cases reported discontinuation of treatment (19 related to Asbroder AEs, and four related to Cerezyme AEs). Infusion-associated reactions occurred in 25/132 cases (17 Asbroder related, six Cerezyme related, two indeterminate). CONCLUSIONS: This analysis demonstrates two potential consequences of identical INN use between Cerezyme and Asbroder: (1) an aggregate safety profile for Cerezyme that includes other products using the identical INN leading to inaccurate pharmacovigilance data and (2) healthcare providers switching, substituting, or potentially assuming interchangeability between the products. Identical INN use without the brand name differentiator may compromise pharmacovigilance data, potentially masking differences in safety profiles between products. The objective of this study was to assess the consequences of multiple drugs using the identical International Nonproprietary Name (INN) “imiglucerase” on adverse event reporting in the Sanofi Genzyme Global Safety Database. The World Health Organization established the INN system to identify drugs that are made of the same pharmaceutical substance and recommends that different products have distinct INN names. The INN imiglucerase was assigned in 1994 to Cerezyme® (Sanofi Genzyme), an orphan drug for the treatment of a rare disease known as Gaucher disease. In 2015, Asbroder® (ISU Abxis) was approved for Gaucher disease in Mexico and has adopted the INN imiglucerase. It was not approved as a biosimilar to Cerezyme. Most importantly, in a significant proportion of the adverse event cases reported, patients received a combination therapy of Asbroder and Cerezyme or Asbroder and “imiglucerase”, suggesting that the shared INN may have led to misconceived interchangeability of these products. Such confusion among healthcare providers poses a potentially serious risk to patient safety and health. These results are especially worrisome because they relate to products sharing an INN that were not approved as biosimilars. The findings from this study are also consistent with the view that Cerezyme and Asbroder may have different safety profiles. The implications of drug products having the same INN are discussed in the article as well as recommended solutions. To our knowledge, this is one of the first reports on real-world safety experience with biologics sharing the same INN name.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Tsang SF, Pandya S, Barakov K, et al. Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database. Drug Saf. 2022. PMID: 35020177. doi:10.1007/s40264-021-01125-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。